{"id":530679,"date":"2021-02-17T16:54:01","date_gmt":"2021-02-17T16:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=530679"},"modified":"2021-02-17T16:54:01","modified_gmt":"2021-02-17T16:54:01","slug":"adrenoleukodystrophy-competitive-landscape-report-2020-emerging-therapies-and-key-pharma-players-involved","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adrenoleukodystrophy-competitive-landscape-report-2020-emerging-therapies-and-key-pharma-players-involved_530679.html","title":{"rendered":"Adrenoleukodystrophy Competitive Landscape Report 2020: Emerging Therapies and Key Pharma Players Involved"},"content":{"rendered":"
\"Adrenoleukodystrophy<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
Adrenoleukodystrophy Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided, which includes the disease overview and Adrenoleukodystrophy treatment guidelines.\n<\/div>\n

DelveInsight launched a new report on Adrenoleukodystrophy Pipeline Insights, 2020<\/strong><\/a>.<\/p>\n

“Adrenoleukodystrophy Pipeline Insight, 2020<\/strong><\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy <\/strong>market. A detailed picture of the Adrenoleukodystrophy <\/strong>pipeline landscape is provided, which includes the disease overview and Adrenoleukodystrophy <\/strong>treatment guidelines.<\/p>\n

\"\"<\/p>\n

Adrenoleukodystrophy (ALD) <\/strong>is a rare genetic condition that causes the buildup of very long chain fatty acids (VLCFAs) in the brain. When VLCFAs accumulate, they destroy the protective myelin sheath around nerve cells, responsible for brain function. Without the myelin sheath, the nerves can no longer relay information to and from the brain. The defective gene in ALD, commonly referred to as a genetic mutation, can cause several different but related conditions: adrenomyelopathy (AMN), Addison’s disease and — the most common and most devastating form — cerebral ALD. Cerebral ALD strikes boys between ages 4 and 10, leading to permanent disability and death usually within four to eight years. There are three distinct types of X-linked adrenoleukodystrophy: a childhood cerebral form, an adrenomyeloneuropathy type, and a form called Addison disease only.<\/p>\n

Request for a detailed sample copy of the report: https:\/\/www.delveinsight.com\/sample-request\/adrenoleukodystrophy-pipeline-insight<\/span><\/a><\/strong><\/p>\n

Signs and symptoms:<\/strong><\/p>\n

1. Progressive stiffness and weakness in the legs (paraparesis)<\/p>\n

2. Experience urinary and genital tract disorders<\/p>\n

3. Often show changes in behavior and thinking ability<\/p>\n

4. Adrenocortical insufficiency<\/p>\n

5. Damage to the brain and nervous system<\/p>\n

Emerging therapies:<\/strong><\/p>\n

1. MGTA-456<\/p>\n

2. OP 101<\/p>\n

3. Elivaldogene autotemcel<\/p>\n

Key pharma players involved:<\/strong><\/p>\n

1. Magenta Therapeutics, Inc.<\/p>\n

2. Ashvattha Therapeutics<\/p>\n

3. bluebird bio<\/p>\n

Adrenoleukodystrophy Pipeline insights<\/a> report provides an assessment of mono and combination therapies by Stage. Number of mono and combination products present in different phases has been provided in graphical as well as tabulated form.<\/strong><\/p>\n

Click here and download free sample pages of the report.<\/strong><\/a><\/p>\n

Table of contents:<\/strong><\/p>\n

1. Report Introduction<\/p>\n

2. Adrenoleukodystrophy  <\/p>\n

3. Adrenoleukodystrophy Current Treatment Patterns<\/p>\n

4. Adrenoleukodystrophy  – DelveInsight’s Analytical Perspective<\/p>\n

5. Therapeutic Assessment<\/p>\n

6. Adrenoleukodystrophy Late Stage Products (Phase-III)<\/p>\n

7. Adrenoleukodystrophy Mid Stage Products (Phase-II)<\/p>\n

8. Early Stage Products (Phase-I)<\/p>\n

9. Pre-clinical Products and Discovery Stage Products<\/p>\n

10. Inactive Products<\/p>\n

11. Dormant Products<\/p>\n

12. Adrenoleukodystrophy Discontinued Products<\/p>\n

13. Adrenoleukodystrophy  Product Profiles<\/p>\n

14. Adrenoleukodystrophy Key Companies<\/p>\n

15. Adrenoleukodystrophy Key Products<\/p>\n

16. Dormant and Discontinued Products<\/p>\n

17. Adrenoleukodystrophy Unmet Needs<\/p>\n

18. Adrenoleukodystrophy  Future Perspectives<\/p>\n

19. Adrenoleukodystrophy  Analyst Review  <\/p>\n

20. Appendix<\/p>\n

21. Report Methodology<\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span> <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP Adrenoleukodystrophy Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided, which includes the disease … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-530679","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/530679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=530679"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/530679\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=530679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=530679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=530679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}